

<b>File reference</b>	W18FOI337
<b>Key words</b>	Urothelial Cell Cancer
<b>Date of release</b>	04/10/2018
<b>Attachments</b>	Yes

## **Freedom of Information Act Disclosure log - Reply Extract**

**You asked**

**We are conducting a piece of research into Urothelial Cell Cancer. Under the Freedom of Information Act 2000 we would like to request the information contained in the attached document.**

**Please see template attached for your completion. Please note the updated time period.**

**For the avoidance of doubt, we do not require any information that may identify individual patients, clinicians or pharmacists or that may otherwise be categorized as personal data.**

Please refer to the attached document noting the legal text below.

### **Legal notes**

University Hospitals Plymouth NHS Trust is confirming in accordance with section 1 (a) of the Act that it holds the information requested and is supplying it in accordance with section 1(b) unless otherwise specified.

Please find the answers to your questions noting that we have redacted the data set where numbers are five or fewer. This avoids a breach of the first two Data Protection Act principles and the general right to object to processing. This refusal is in accordance with section 40.-(2)(a) and (b) by virtue of the first and second condition.

**Attachments included:** No

**28FOI337 response from University Hospitals Plymouth NHS Trust- FOI Request re Urothelial Cancer Patients**

**Please indicate the number of metastatic or locally advanced Urothelial<sup>1</sup> cancer patients treated<sup>2</sup> by your Trust in the 3 months, April 2018 to June 2018 inclusive.**

**If data is not held in a sufficient way within your Trust systems, i.e. if for example you are unable to distinguish between cancer type and/or stage, please indicate accordingly within the tables below.**

	<b>Total number treated</b> (Metastatic/locally advanced Urothelial patients)	<b>If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:</b>	
Total number of metastatic or locally advanced Urothelial cancer (UCC, transitional carcinoma, TCC) patients treated	16 (counted anyone with ICD10 codes C65,C66,C67,C68 – based on info given below)	Total Urothelial Cancer patients (any stage)	16
		Other (please specify)	
		Data not held/accessible	

**Of the metastatic or locally advanced Urothelial cancer patients treated by your Trust in the 3 months, April 2018 to June 2018 inclusive, please indicate the number treated with the following therapies.**

<b>Therapy</b>	<b>Total number treated</b> (Metastatic/locally advanced Urothelial patients)	<b>If unable to provide number of metastatic/locally advanced Urothelial patients, please indicate the level at which data has been provided:</b>	
Cisplatin (mono or combination therapy)		Total Urothelial Cancer patients (any stage)	6
		Other (please specify)	
		Data not held/accessible	
Carboplatin (mono or combination therapy)	Five or fewer (counted anyone with ICD10 codes C65,C66,C67,C68 – based on info	Total Urothelial Cancer patients (any stage)	Five or fewer
		Other (please specify)	

<sup>1</sup> ICD10 C65, C66, C67, C68; TNM staging for metastatic Urothelial Cancer = Any T, any N, M1; TNM staging for locally advanced Urothelial Cancer = Any T, N2-3, M0 or T4b, any N, M0; Please include numbers for:

- any diagnosis of metastatic disease as opposed to patients that present with metastases
- all metastatic sites from a Urothelial primary

<sup>2</sup> Please indicate the number of patients (excluding clinical trial patients) treated with any active anti-cancer drug treatment.

	given below)	Data not held/accessible	
Pembrolizumab (Keytruda)		Total Urothelial Cancer patients (any stage)	
		Other (please specify)	
		Data not held/accessible	
Atezolizumab (Tecentriq)	Five or fewer (counted anyone with ICD10 codes C65,C66,C67,C68 – based on info given below)	Total Urothelial Cancer patients (any stage)	Five or fewer
		Other (please specify)	
		Data not held/accessible	

**If your trust does not treat these cancers and you refer your patients to another trust, please state to which trust(s) patients are referred: Not applicable**